Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold
NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the combo shot reported nerve damage.
FDA Puts Clinical Hold On Novavax COVID-19-Influenza Combo Vaccine Candidate; Stock Tumbles
Wednesday said the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its COVID-19-Influenza
Novavax stock plunges as FDA puts clinical hold on COVID-flu combo vaccine
Novavax shares plummet 30% as FDA places clinical hold on COVID-19 and influenza combination vaccine due to serious adverse event.
Novavax Says FDA Puts Clinical Hold on Covid-19, Flu Vaccines
Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and standalone flu inoculation, sending shares down sharply.
Novavax says FDA put hold on combination Covid-flu shot and influenza vaccine; shares plunge
The so-called clinical hold is due to a single report of nerve damage in a patient who received the combination shot in a phase two trial.
FDA halts Novavax's vaccine trials after safety scare
The U.S. Food and Drug Administration (FDA) has suspended Novavax's experimental combined COVID-19 and flu vaccine clinical trials. This decision followed reports of a participant's symptoms of nervous system damage,
Novavax shares sink as US FDA puts trial of combo COVID-flu vaccine on hold
Shares in Novavax (NASDAQ:NVAX) slumped in premarket US trading on Wednesday after the US Food and Drug Administration placed a trial of its experimental COVID-19 and influenza vaccine combination on hold.
bovnews3h
NVAX Unveiled: The Shocking Truth Behind Novavax Inc’s Latest Stock Movements
On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.15 which represents a decrease of $-2.45 or -19.44% from the prior close of $12.6. The stock opened at $10.43 and touched a ...
Novavax’s Regulatory Setback and Mid-Term Underperformance: An Analyst’s Perspective
Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.
FDA Puts Speed Breaker On Novavax's COVID/Flu Combo Shot Trial On Concerns Related To Damaged Nerves
Novavax Inc. (NASDAQ:NVAX) stock is trading lower on Wednesday. The FDA has placed a clinical hold on Novavax’s ...
Hosted on MSN17h
Novavax (NASDAQ:NVAX) Stock Drops 18% after Clinical Trial Is Halted
Shares of pharmaceutical company Novavax ($NVAX) are down 18% on news that the U.S. Food and Drug Administration (FDA) has ...
news.stocktradersdaily5h
Trading (NVAX) With Integrated Risk Controls
Check the time stamp on this data. Updated AI-Generated Signals for Novavax Inc. (NVAX) available here: NVAX.
kalkinemedia7h
Novavax, Inc. (NASDAQ:NVAX) Shares Tumbled on Wednesday Following Clinical Hold on Flu Combination Vaccine
Highlights,Novavax faces a clinical hold following the report of motor neuropathy in a trial participant nearly two years ...
SchaeffersResearch.com20h
3 Vaccine Stocks to Watch as Flu Season Approaches
Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring. Earlier today, ...
bovnews2d
Why Did Novavax Inc (NVAX) Stock See -17.13% Plunge in the Last 90 Days?
On Friday, Novavax Inc (NVAX) stock saw a decline, ending the day at $12.53 which represents a decrease of $-0.37 or -2.87% from the prior close of $12.9. The stock opened at $12.72 and touched a low ...
Buy Rating Affirmed for Novavax Amid Strategic Alliances and Promising Vaccine Trials
Novavax (NVAX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mayank Mamtani ...